Cellectis S.A. (CLLS)

3,2400 +0,1400 (+4,52%) Alla chiusura: 04:00PM EDT

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Andre Choulika Ph.D.	Co-Founder, CEO & Director	876,6k	N/D	1965
Dr. David j. d. Sourdive Ph.D.	Deputy CEO, Executive VP of CMC & Manufacturing and Director	557,84k	N/D	1967
Dr. Bing C. Wang M.B.A., Ph.D.	Chief Financial Officer	N/D	N/D	1977
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	N/D	N/D	N/D
Mr. Jean Charles Epinat	Chief Technological Officer	N/D	N/D	N/D
Dr. Philippe Duchateau Ph.D.	Chief Scientific Officer	N/D	N/D	1963
Mr. Stephan Reynier M.Sc.	Chief Regulatory & Pharmaceutical Compliance Officer	N/D	N/D	1969
Ms. Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	N/D	N/D	1982
Pascalyne Wilson	Director of Communications	N/D	N/D	N/D
Ms. Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer	N/D	N/D	1970

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 to treat relapsed or refractory for non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia; ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL, as well as cemacabtagene ansegedleucel products as part of a first line treatment plan for newly diagnosed and treated large B cell lymphoma patients who are likely to relapse and need further therapy. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; joint research and collaboration agreement with AZ Ireland; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and investment agreement with AstraZeneca. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Governance aziendale

L'ISS Governance QualityScore di Cellectis S.A. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 9; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.